Novo Nordisk announced refunds for 340B overcharges on six NDCs including one for Fiasp insulin.

Drug Manufacturer 340B Overcharge Notices Reach New Record, Novo Nordisk Is the Latest

With more than six months to go in the year, the number of refunds that drug manufacturers have had to provide to 340B providers has already topped the previous annual record of 17.  Drug manufacturer Novo Nordisk becomes the 21st manufacturer to post a notice on the U.S. Health Resources and Services Administration (HRSA) website.

Novo Nordisk, which is based in Denmark, says in its notice that it is providing 340B covered entities refunds for overcharges on six NDCs during Q3 2019 “due to revisions made to its Medicaid pricing data.” The refunds are for purchases of Saxenda (for child obesity), Fiasp (insulin), and Ozempic and Victoza (non-insulin antidiabetics).  

With more than six months to go in the year, the number of refunds that drug manufacturers have had to provide to 340B providers has already topped the previous annual record of 17.  Drug manufacturer Novo Nordisk becomes the 21st manufacturer to post a notice on the U.S. Health Resources and Services Administration website.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer